{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:06:43Z","timestamp":1766869603336,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-02373"],"award-info":[{"award-number":["2016-02373"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2017\/340"],"award-info":[{"award-number":["CAN2017\/340"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent evidence suggests that cholera toxin might have multiple functions regarding the ability to regulate the immune system. However, it is unknown whether subsequent administration of cholera vaccine might affect the mortality rate in patients with prostate cancer. Here we report that patients in Sweden, who were diagnosed with prostate cancer between July 2005 and December 2014 and used cholera vaccine, have a decreased risk of death from prostate cancer (HR, 0.57; 95% CI, 0.40\u20130.82) as compared to patients with prostate cancer but without cholera vaccine use, adjusted for a range of confounding factors. In addition, patients using cholera vaccine show a decreased risk of death overall (HR, 0.53; 95% CI, 0.41\u20130.69). The decreased mortality rate is largely consistent, irrespective of patients\u2019 age or tumor stage at diagnosis. In this population-based study, we suggest that subsequent administration of cholera vaccine after prostate cancer diagnosis might reduce the mortality rate.<\/jats:p>","DOI":"10.1038\/s41467-018-04814-4","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T10:47:16Z","timestamp":1528800436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-9496","authenticated-orcid":false,"given":"Jianguang","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"4814_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis, R. et al. Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE\u20135-a population-based study. Lancet Oncol. 15, 23\u201334 (2014).","journal-title":"Lancet Oncol."},{"key":"4814_CR2","doi-asserted-by":"publisher","first-page":"djx030","DOI":"10.1093\/jnci\/djx030","volume":"109","author":"A Jemal","year":"2017","unstructured":"Jemal, A. et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J. Natl Cancer. Inst. 109, djx030 (2017).","journal-title":"J. Natl Cancer. Inst."},{"key":"4814_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/carcin\/bgu325","volume":"36","author":"M Doulberis","year":"2015","unstructured":"Doulberis, M. et al. Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer. Carcinogenesis 36, 280\u2013290 (2015).","journal-title":"Carcinogenesis"},{"key":"4814_CR4","first-page":"179","volume":"133","author":"K Bharati","year":"2011","unstructured":"Bharati, K. & Ganguly, N. K. Cholera toxin: a paradigm of a multifunctional protein. Indian J. Med. Res. 133, 179\u2013187 (2011).","journal-title":"Indian J. Med. Res."},{"key":"4814_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/toxins7030974","volume":"7","author":"KJ Baldauf","year":"2015","unstructured":"Baldauf, K. J. et al. Cholera toxin B: one subunit with many pharmaceutical applications. Toxins 7, 974\u2013996 (2015).","journal-title":"Toxins"},{"key":"4814_CR6","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.4049\/jimmunol.169.11.6408","volume":"169","author":"P Chen","year":"2002","unstructured":"Chen, P. et al. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169, 6408\u20136416 (2002).","journal-title":"J. Immunol."},{"key":"4814_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1053\/j.gastro.2017.09.009","volume":"154","author":"J Ji","year":"2018","unstructured":"Ji, J., Sundquist, J., & Sundquist, K. Cholera vaccine use is associated with a reduced risk of death in patients with colorectal cancer: a population-based study. Gastroenterology\u00a0154, 86\u201392.e1\u00a0(2018).","journal-title":"Gastroenterology"},{"key":"4814_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1348-0421.2005.tb03632.x","volume":"49","author":"I Isomura","year":"2005","unstructured":"Isomura, I. et al. Recombinant cholera toxin B subunit activates dendritic cells and enhances antitumor immunity. Microbiol. Immunol. 49, 79\u201387 (2005).","journal-title":"Microbiol. Immunol."},{"key":"4814_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1189\/jlb.1103534","volume":"75","author":"EC Lavelle","year":"2004","unstructured":"Lavelle, E. C. et al. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75, 756\u2013763 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"4814_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/2051013615613473","volume":"3","author":"K Wiedinger","year":"2015","unstructured":"Wiedinger, K., Romlein, H. & Bitsaktsis, C. Cholera toxin B induced activation of murine macrophages exposed to a fixed bacterial immunogen. Ther. Adv. Vaccines 3, 155\u2013163 (2015).","journal-title":"Ther. Adv. Vaccines"},{"key":"4814_CR11","doi-asserted-by":"crossref","unstructured":"Block, M. I., Alexander, H. R., & Norton, J. A. Cholera toxin pretreatment protects against tumor necrosis factor lethality without compromising tumor response to therapy. Arch. Surg. 127 1330\u20131334 (1992).","DOI":"10.1001\/archsurg.1992.01420110078016"},{"key":"4814_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1272\/jnms.77.50","volume":"77","author":"A Wakabayashi","year":"2010","unstructured":"Wakabayashi, A. et al. Development of antitumor immunity by oral vaccination with tumor antigen and cholera toxin. J. Nippon Med. Sch. 77, 50\u201352 (2010).","journal-title":"J. Nippon Med. Sch."},{"key":"4814_CR13","first-page":"3340","volume":"52","author":"G Kaur","year":"1992","unstructured":"Kaur, G. et al. Growth inhibition by cholera toxin of human lung carcinoma cell lines: correlation with GM1 ganglioside expression. Cancer Res. 52, 3340\u20133346 (1992).","journal-title":"Cancer Res."},{"key":"4814_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/aps.2011.31","volume":"32","author":"Q Xia","year":"2011","unstructured":"Xia, Q. et al. Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX\/LPA axis. Acta Pharmacol. Sin. 32, 1055\u20131062 (2011).","journal-title":"Acta Pharmacol. Sin."},{"key":"4814_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","volume":"12","author":"F Bertolini","year":"2015","unstructured":"Bertolini, F., Sukhatme, V. P. & Bouche, G. Drug repurposing in oncology\u2014patient and health systems opportunities. Nat. Rev. Clin. Oncol. 12, 732\u2013742 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4814_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.euf.2016.05.004","volume":"3","author":"TJ Murtola","year":"2017","unstructured":"Murtola, T. J. et al. Statin use and prostate cancer survival in the finnish randomized study of screening for prostate cancer. Eur. Urol. Focus 3, 212\u2013220\u00a0(2017).","journal-title":"Eur. Urol. Focus"},{"key":"4814_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/pros.23138","volume":"76","author":"T Keskivali","year":"2016","unstructured":"Keskivali, T. et al. Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate 76, 469\u2013478 (2016).","journal-title":"Prostate"},{"key":"4814_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ctrv.2015.04.005","volume":"41","author":"S Zhong","year":"2015","unstructured":"Zhong, S. et al. Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat. Rev. 41, 554\u2013567 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"4814_CR19","doi-asserted-by":"publisher","first-page":"e1644","DOI":"10.1097\/MD.0000000000001644","volume":"94","author":"LM Sun","year":"2015","unstructured":"Sun, L. M. et al. Statin use reduces prostate cancer all-cause mortality: a nationwide population-based cohort study. Medicine 94, e1644 (2015).","journal-title":"Medicine"},{"key":"4814_CR20","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1055-9965.EPI-14-0056","volume":"23","author":"L Bensimon","year":"2014","unstructured":"Bensimon, L. et al. The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol. Biomarkers Prev. 23, 2111\u20132118 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"4814_CR21","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","volume":"31","author":"D Margel","year":"2013","unstructured":"Margel, D. et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 31, 3069\u20133075 (2013).","journal-title":"J. Clin. Oncol."},{"key":"4814_CR22","doi-asserted-by":"publisher","first-page":"e71583","DOI":"10.1371\/journal.pone.0071583","volume":"8","author":"M Franciosi","year":"2013","unstructured":"Franciosi, M. et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE 8, e71583 (2013).","journal-title":"PLoS ONE"},{"key":"4814_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JCO.2013.49.4757","volume":"32","author":"O Yu","year":"2014","unstructured":"Yu, O. et al. Use of statins and the risk of death in patients with prostate cancer. J. Clin. Oncol. 32, 5\u201311 (2014).","journal-title":"J. Clin. Oncol."},{"key":"4814_CR24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3109\/0284186X.2013.831474","volume":"52","author":"RV Karlsen","year":"2013","unstructured":"Karlsen, R. V. et al. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta Oncol. 52, 1609\u20131614 (2013).","journal-title":"Acta Oncol."},{"key":"4814_CR25","doi-asserted-by":"crossref","unstructured":"Baldauf, K. J. et al. Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon. Mucosal Immunol. 10, 887\u2013900 (2017).","DOI":"10.1038\/mi.2016.95"},{"key":"4814_CR26","doi-asserted-by":"crossref","first-page":"34537","DOI":"10.18632\/oncotarget.5307","volume":"6","author":"W Lu","year":"2015","unstructured":"Lu, W. et al. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit. Oncotarget 6, 34537\u201334548 (2015).","journal-title":"Oncotarget"},{"key":"4814_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0264-410X(02)00348-1","volume":"21","author":"HO Hallander","year":"2002","unstructured":"Hallander, H. O. et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 21, 138\u2013145 (2002).","journal-title":"Vaccine"},{"key":"4814_CR28","unstructured":"World Health Organization. Future needs and directions for Shigella vaccines (Besoins et orientations futurs en mati\u00e8re de vaccins anti-Shigella). Wkly. Epidemiol. Rec. (Relev. Epidemiol. Hebd.)\u00a081, 51\u201358 (2006)."},{"key":"4814_CR29","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1086\/315051","volume":"180","author":"R Lagos","year":"1999","unstructured":"Lagos, R. et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180, 1709\u20131712 (1999).","journal-title":"J. Infect. Dis."},{"key":"4814_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-9378-8-42","volume":"8","author":"ES Amirian","year":"2013","unstructured":"Amirian, E. S. et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect. Agents Cancer 8, 42 (2013).","journal-title":"Infect. Agents Cancer"},{"key":"4814_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2017.08.039","volume":"111","author":"DM Golombos","year":"2018","unstructured":"Golombos, D. M. et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 111, 122\u2013128 (2018).","journal-title":"Urology"},{"key":"4814_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2011.07.009","volume":"48","author":"A Berglund","year":"2012","unstructured":"Berglund, A. et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur. J. Cancer 48, 75\u201384 (2012).","journal-title":"Eur. J. Cancer"},{"key":"4814_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-10-9","volume":"10","author":"F Eek","year":"2010","unstructured":"Eek, F. et al. Differences in socioeconomic and gender inequalities in tobacco smoking in Denmark and Sweden; a cross sectional comparison of the equity effect of different public health policies. BMC Public Health 10, 9 (2010).","journal-title":"BMC Public Health"},{"key":"4814_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1017\/S0007114515004110","volume":"115","author":"E Ax","year":"2016","unstructured":"Ax, E. et al. Dietary patterns in Swedish adults; results from a national dietary survey. Br. J. Nutr. 115, 95\u2013104 (2016).","journal-title":"Br. J. Nutr."},{"key":"4814_CR35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/jnci\/djs168","volume":"104","author":"J Ji","year":"2012","unstructured":"Ji, J., Sundquist, K. & Sundquist, J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J. Natl. Cancer Inst. 104, 790\u2013792 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"4814_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-007-9611-y","volume":"108","author":"K Hemminki","year":"2008","unstructured":"Hemminki, K. et al. Risk of familial breast cancer is not increased after pregnancy. Breast Cancer Res. Treat. 108, 417\u2013420, (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"4814_CR37","doi-asserted-by":"crossref","unstructured":"Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. (eds). TNM Classification of Malignant Tumours, 7th edn (Wiley-Blackwell, 2011).","DOI":"10.1002\/9780471420194.tnmc26.pub2"},{"key":"4814_CR38","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jnci\/djt211","volume":"105","author":"J Chubak","year":"2013","unstructured":"Chubak, J. et al. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J. Natl. Cancer Inst. 105, 1456\u20131462 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"4814_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/bimj.200410152","volume":"47","author":"A Latouche","year":"2005","unstructured":"Latouche, A., Porcher, R. & Chevret, S. A note on including time-dependent covariate in regression model for competing risks data. Biom. J. 47, 807\u2013814 (2005).","journal-title":"Biom. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04814-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:41:13Z","timestamp":1671547273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04814-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["4814"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-04814-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"type":"electronic","value":"2041-1723"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"16 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2367"}}